

Registered number  
11501098

AGILE BIOREG LTD

Filleted Accounts

31 July 2020

**AGILE BIOREG LTD****Registered number:** 11501098**Balance Sheet****as at 31 July 2020**

	Notes	2020	2019
		£	£
<b>Current assets</b>			
Debtors	3	100	7,138
Cash at bank and in hand		54,365	72,419
		<u>54,465</u>	<u>79,557</u>
<b>Creditors: amounts falling due within one year</b>	4	(12,674)	(23,811)
<b>Net current assets</b>		<u>41,791</u>	<u>55,746</u>
<b>Net assets</b>		<u>41,791</u>	<u>55,746</u>
<b>Capital and reserves</b>			
Called up share capital		100	100
Profit and loss account		41,691	55,646
<b>Shareholder's funds</b>		<u>41,791</u>	<u>55,746</u>

The director is satisfied that the company is entitled to exemption from the requirement to obtain an audit under section 477 of the Companies Act 2006.

The member has not required the company to obtain an audit in accordance with section 476 of the Act.

The director acknowledges her responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of accounts.

The accounts have been prepared and delivered in accordance with the special provisions applicable to companies subject to the small companies regime. The profit and loss account has not been delivered to the Registrar of Companies.

Dr.A. LITSIOU

Director

Approved by the board on 9 January 2021

# **AGILE BIOREG LTD**

## **Notes to the Accounts**

**for the year ended 31 July 2020**

### **1 Accounting policies**

#### ***Basis of preparation***

The accounts have been prepared under the historical cost convention and in accordance with FRS 102, The Financial Reporting Standard applicable in the UK and Republic of Ireland (as applied to small entities by section 1A of the standard).

#### ***Going Concern***

On March 2020, the World Health Organisation formally recognised COVID-19 as a pandemic. The implications of COVID-19 resulted in many governments across the world deciding to close down non-essential operations, which will have a great impact on the global economy. At the date of approving the financial statements, due to the corrective action taken to reduce expenses and preserve cash, the pandemic has not resulted in a significant impact to the Company's access to liquidity to manage operations on an ongoing basis.

#### ***Turnover***

Turnover is measured at the fair value of the consideration received or receivable, net of discounts and value added taxes. Turnover includes revenue earned from the rendering of services. Turnover from the rendering of services is recognised by reference to the stage of completion of the contract. The stage of completion of a contract is measured by comparing the costs incurred for work performed to date to the total estimated contract costs.

#### ***Debtors***

Short term debtors are measured at transaction price (which is usually the invoice price), less any impairment losses for bad and doubtful debts. Loans and other financial assets are initially recognised at transaction price including any transaction costs and subsequently measured at amortised cost determined using the effective interest method, less any impairment losses for bad and doubtful debts.

#### ***Creditors***

Short term creditors are measured at transaction price (which is usually the invoice price). Loans and other financial liabilities are initially recognised at transaction price net of any transaction costs and subsequently measured at amortised cost determined using the effective interest method.

#### ***Taxation***

A current tax liability is recognised for the tax payable on the taxable profit of the current and past periods. A current tax asset is recognised in respect of a tax loss that can be carried back to recover tax paid in a previous period. Deferred tax is recognised in respect of all timing differences between the recognition of income and expenses in the financial statements and their inclusion in tax assessments. Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits. Deferred tax is measured using the tax rates and laws that have been enacted or substantively enacted by the reporting date and that are expected to apply to the reversal of the timing difference, except for revalued land and investment property where the tax rate that applies to the sale of the asset is used. Current and deferred tax assets and liabilities are not discounted.

<b>2 Employees</b>	<b>2020</b>	<b>2019</b>
	<b>Number</b>	<b>Number</b>
Average number of persons employed by the company	<u>1</u>	<u>1</u>

<b>3 Debtors</b>	<b>2020</b>	<b>2019</b>
	<b>£</b>	<b>£</b>
Trade debtors	-	4,200
Other debtors	<u>100</u>	<u>2,938</u>
	<u>100</u>	<u>7,138</u>

<b>4 Creditors: amounts falling due within one year</b>	<b>2020</b>	<b>2019</b>
	<b>£</b>	<b>£</b>
Taxation and social security costs	12,674	23,218
Other creditors	<u>-</u>	<u>593</u>
	<u>12,674</u>	<u>23,811</u>

## **5 Other information**

AGILE BIOREG LTD is a private company limited by shares and incorporated in England. Its registered office is:

Suite 7

155 Minories

London

England

EC3N 1AD

This document was delivered using electronic communications and authenticated in accordance with the registrar's rules relating to electronic form, authentication and manner of delivery under section 1072 of the Companies Act 2006.